Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen

2003

Clinical Significance of TP53, BCL-2, BAX, and MEK1 in Ovarian Cancer

Sample size: 229 publication 10 minutes Evidence: moderate

Author Information

Author(s): Kupryjańczyk J, Szymańska T, Mądry R, Timorek A, Stelmachów J, Karpińska G, Rembiszewska A, Ziółkowska I, Kraszewska E, Dębniak J, Emerich J, Ułańska M, Płużańska A, Jędryka M, Goluda M, Chudecka-Głaz A, Rzepka-Górska I, Klimek M, Urbański K, Bręborowicz J, Zieliński J, Markowska J

Primary Institution: Institute of Oncology, Warsaw, Poland

Hypothesis

The study aims to evaluate the clinical significance of TP53, BCL-2, BAX, and MEK1 expression in ovarian carcinomas treated with platinum-based chemotherapy.

Conclusion

The study found that TP53 protein accumulation and the expression of apoptosis-related proteins have significant implications for the response to chemotherapy in ovarian cancer.

Supporting Evidence

TP53 protein accumulation was observed in 135 (59%) tumours.
BCL-2 was negative in 156 (68%) cases.
BAX expression was low in 85 (37%) cases.
MEK1 expression was low in 52 tumours (23%).
Complete remission was achieved in 120 patients (52%).
Overall survival was influenced by patient age, FIGO stage, and residual tumour size.
High BAX expression was associated with longer disease-free survival in TP53-positive patients.
Clinical parameters were the strongest predictors of chemotherapy response.

Takeaway

This study looked at how certain proteins in ovarian cancer cells affect how well patients respond to chemotherapy. It found that some proteins can help predict treatment success.

Methodology

The study analyzed archival ovarian carcinomas from 229 patients, evaluating protein expression through immunohistochemical analysis and assessing clinical response to chemotherapy.